Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Q1 2022 Earnings Presentation
20 slides from Novo Nordisk A/s Class B's earnings presentation, Apr 29, 2022
Slide 1: Novo Nordisk – a focused healthcare company
Novo Nordisk – a focused healthcare company Investor presentation First three months of 2022 Morten Kruse Jacobsen (to the right), Senior Director at Novo Nordisk and married to Anders. Being a sustainable employer is a key priority for Novo Nordisk. This includes fostering a diverse and inclusive w
Slide 2: Agenda
2 Investor presentation First three months of 2022 Novo Nordisk® Progress on Strategic Aspirations 2025 Agenda Agenda Commercial execution Innovation and therapeutic focus Financials
Slide 3: Forward-looking statements
3 Investor presentation First three months of 2022 Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2021 and Form 20-F, which both were filed with the SEC in February 2022
Slide 4: Strategic Aspirations 2025 | Highlights first three months 2022
4 Investor presentation First three months of 2022 Novo Nordisk® Strategic Aspirations 2025 | Highlights first three months 2022 Progress towards zero environmental impact: Further raise innovation bar for Diabetes treatment: • Carbon emissions increased by 46% vs first quarter of • Approval of Ozem
Slide 5: Sales growth of 18% driven by both operating units and by all therapy areas
5 Investor presentation First three months of 2022 Novo Nordisk® Sales growth of 18% driven by both operating units and by all therapy areas Reported geographic sales split for first quarter of 2022 Reported therapy area sales and growth for first quarter of 2022 DKK Insulin GLP-1 Other diabetes DKK
Slide 6: Diabetes value market leadership increased by 1.2%-points to 30.5%
6 Investor presentation First three months of 2022 Novo Nordisk® Diabetes value market leadership increased by 1.2%-points to 30.5% Novo Nordisk global diabetes value market share Diabetes value market leadership expansion driven by the GLP-1 franchise 60% Diabetes GLP-1 Insulin Diabetes care sales
Slide 7: International Operations Diabetes care sales grew across all regions, mainly driven by GLP-1 performance
7 Investor presentation First three months of 2022 Novo Nordisk® International Operations Diabetes care sales grew across all regions, mainly driven by GLP-1 performance Reported Diabetes care sales and growth per IO geography GLP-1 patients and value market share in IO DKK Number of Value market bi
Slide 8: New GLP-1 prescriptions in the US have accelerated in the first quarter of 2022
8 Investor presentation First three months of 2022 Novo Nordisk® New GLP-1 prescriptions in the US have accelerated in the first quarter of 2022 US GLP-1 weekly NBRx prescriptions US GLP-1 TRx market share Weekly NBRx Total GLP-1 scripts (‘000) TRx share Class growth +30% scripts (‘000) 40 60% 3.500
Slide 9: Obesity care sales grew by 107% in the first quarter of 2022
9 Investor presentation First three months of 2022 Novo Nordisk® Obesity care sales grew by 107% in the first quarter of 2022 Global market growth and market share within Obesity care Reported Obesity care sales split DKK billion DKK billion 42%1 3%1 55%1 107% 3.4 90% 3 82% 2.5 1,4 2,4 2.4 60% 2.0 0
Slide 10: During the first quarter, weekly prescriptions of Wegovy in the US exceeded 20,000
10 Investor presentation First three months of 2022 Novo Nordisk® During the first quarter, weekly prescriptions of Wegovy® in the US exceeded 20,000 Branded AOM TRx in the US Wegovy® in the US TRx count (000s) 48 40 44.5 32 24.8 • Commercial formulary access around 80% 24 • The three lowest dose st
Slide 11: Rare disease sales grew by 3% driven by both North America Operations and International Operations
11 Investor presentation First three months of 2022 Novo Nordisk® Rare disease sales grew by 3% driven by both North America Operations and International Operations Reported Rare disease sales Rare disease sales driven by global commercial execution DKK Growth at CER Rare disease sales growth driven
Slide 12: Semaglutide 2.0 mg label reflects superior HbA1c reduction with similar number of GI side-effects
12 Investor presentation First three months of 2022 Novo Nordisk® Semaglutide 2.0 mg label reflects superior HbA1c reduction with similar number of GI side-effects as semaglutide 1.0 mg Results reflected in the approved label for Ozempic® 2.0 mg • Approved for treatment of type 2 diabetes in adults
Slide 13: ONWARDS completed as the first of six trials in the phase 3 programme for once-weekly insulin icodec
13 Investor presentation First three months of 2022 Novo Nordisk® ONWARDS 2 completed as the first of six trials in the phase 3 programme for once-weekly insulin icodec The ONWARDS 2 phase 3a trial has been completed Objective To confirm the efficacy (non-inferiority on HbA1c) and safety of Insulin
Slide 14: ONWARDS met its primary endpoint and demonstrated superiority on HbA1c reduction vs insulin degludec
14 Investor presentation First three months of 2022 Novo Nordisk® ONWARDS 2 met its primary endpoint as well as demonstrated superiority on HbA1c reduction compared to insulin degludec Superior change in HbA1c from baseline over time 26 weeks Key highlights 0,0 Safety Change from baseline (%) • Insu
Slide 15: Concizumab reduced the number of bleeds in adults and adolescents with inhibitors in the Explorer 7 trial
15 Investor presentation First three months of 2022 Novo Nordisk® Concizumab reduced the number of bleeds in adults and adolescents with inhibitors in the Explorer 7 trial Annualised bleeding rate per patient group Key highlights 100 Median Mean Efficacy • Median ABR was 0 for concizumab prophylaxis
Slide 16: R&D milestones for 2022
16 Investor presentation First three months of 2022 Novo Nordisk® R&D milestones for 2022 Clinical milestones1 Regulatory milestones1 F Project Q1 2022 Q2 2022 Q3 2022 Q4 2022 Diabetes care Ozempic® 2.0 mg US decision FDC Sema – OW GIP Phase 1 results CagriSema T2DM Phase 2 results Rybelsus® CN subm
Slide 17: Financial results – First three months of 2022
17 Investor presentation First three months of 2022 Novo Nordisk® Financial results – First three months of 2022 First three First three Change Change In DKK million months of 2022 months of 2021 (reported) (CER) Sales 42,031 33,804 24% 18% Gross profit 35,114 27,993 25% 18% Gross margin 83.5% 82.8%
Slide 18: Financial outlook for 2022
18 Investor presentation First three months of 2022 Novo Nordisk® Financial outlook for 2022 Expectations Expectations 29 April 2022 2 Feb 2022 Sales growth – at CER 10% to 14% 6% to 10% Sales growth - reported Around 7 percentage points higher Around 5 percentage points higher Operating profit grow
Slide 19: Strategic aspirations 2025
19 Investor presentation First three months of 2022 Novo Nordisk® Strategic aspirations 2025 • Further raise the innovation-bar for diabetes treatment therapeutic focus • Progress towards zero environmental impact • Develop a leading portfolio of superior treatment Innovation and solutions for obesi
Slide 20: Investor contact information
20 Investor presentation First three months of 2022 Novo Nordisk® Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on the Novo Nordisk A/S New York Stock Ex